Are there lessons we can learn from BP ? One thin
Post# of 148163
(Total Views: 614)
Posted On: 08/28/2020 8:06:57 AM
Are there lessons we can learn from BP ?
One thing BP seems to do is larger sized trials. This seems to make sense when dealing with gov. orgs. That sort of trial size makes it easier for a public servant to safely say yes, as they can point to the data and not open themselves up to attack or questions. They also seem to be clever with the trial protocols (ie. more reviews and a little bit more dynamic). The more dynamic nature seems to let them have a bet each way (they get possible useable data earlier that may help with an EUA). Could be one of the reasons CD12 has more hope - a trial size of 195 (and eventually 390) is way bigger than 85. It enables a high level public servant to make a call safely. We may not have the resources for n=3000, but could should we start a M/M phase3 anyway with better "review" periods for say n=1000 with reviews every 100 or 200 people ?
One thing BP seems to do is larger sized trials. This seems to make sense when dealing with gov. orgs. That sort of trial size makes it easier for a public servant to safely say yes, as they can point to the data and not open themselves up to attack or questions. They also seem to be clever with the trial protocols (ie. more reviews and a little bit more dynamic). The more dynamic nature seems to let them have a bet each way (they get possible useable data earlier that may help with an EUA). Could be one of the reasons CD12 has more hope - a trial size of 195 (and eventually 390) is way bigger than 85. It enables a high level public servant to make a call safely. We may not have the resources for n=3000, but could should we start a M/M phase3 anyway with better "review" periods for say n=1000 with reviews every 100 or 200 people ?
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼